ACADIA Pharmaceuticals Stock Trading Halted Today
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
Go back to ACADIA Pharmaceuticals Stock Trading Halted Today
March 30, 2016 6:49 AM EDT
Needham & Company reiterated a Buy rating and $49.00 price target on Acadia Pharmaceuticals (NASDAQ: ACAD) following a vote by the FDA Psychopharmacologic Drugs Advisory Committee in favor of Nuplazid approval for treatment of Parkinson's Disease Psychosis. Committee members generally viewed Nuplazid as effective, with a few... More
March 29, 2016 5:43 PM EDT
Acadia Pharma (NASDAQ: ACAD) Resumes Trading at 5:45 PM ET
...
More
March 29, 2016 5:14 PM EDT
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) announced that the U.S. Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee (PDAC) voted 12 to 2 that the benefits of NUPLAZID (pimavanserin) for the treatment of psychosis associated with Parkinsons disease outweigh the risks of... More
March 29, 2016 2:55 PM EDT
Acadia Pharma (NASDAQ: ACAD) received a positive FDA panel vote for pimavanserin in treating at least one disease. The following question was posed Tuesday:
1. VOTE: Has Acadia provided substantial evidence of effectiveness for NUPLAZID (pimavanserin) for the treatment of psychosis w/ PD?
12 panelists voted 'yes,' while 2 voted 'no.'
...
More
March 29, 2016 10:14 AM EDT
Acadia Pharma (NASDAQ: ACAD) is said to be facing tough questions on the efficacy of Nuplazid. The following was posted by pharma-watcher Adam Feuerstein to Twitter on Tuesday:
... More
